BMS Gets First Immunotherapy Approval In Neoadjuvant Lung Cancer, Quickly
Executive Summary
Opdivo gets approved by the US FDA for neoadjuvant non-small cell lung cancer, an important new early-stage indication for the anti-PD-1 agent that cleared the agency in roughly two months.
You may also be interested in...
Can’t Win Them All: Two Merck Oncology Trials Fail
The company stopped a study of Lynparza in colorectal cancer for futility and announced a study of Keytruda/chemoradiation in head-and-neck cancer didn’t meet its primary endpoint.
AstraZeneca Looks To Muscle In On BMS-Dominated Neoadjuvant NSCLC Setting
Without disclosing data, the company reported positive pathological complete response data from the AEGEAN study of its PD-L1 inhibitor Imfinzi in neoadjuvant NSCLC, where BMS’s Opdivo won approval in March.
BMS’s Revlimid Loss Of Exclusivity Is Not As Bad As Expected, But Not For Long
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.